Advertisement

 

 

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation.

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation.
Author Information (click to view)

Pennington B, Marriott ER, Lichtlen P, Akbar A, Hatswell AJ,


Pennington B, Marriott ER, Lichtlen P, Akbar A, Hatswell AJ, (click to view)

Pennington B, Marriott ER, Lichtlen P, Akbar A, Hatswell AJ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

PharmacoEconomics – open 2018 01 04() doi 10.1007/s41669-017-0065-9
Abstract
OBJECTIVE
The objective of this study was to evaluate the cost effectiveness of lubiprostone, prucalopride, placebo and immediate referral to secondary care in chronic idiopathic constipation (CIC) in an economic model that was used by the UK National Institute for Health and Care Excellence (NICE) in developing guidance.

METHODS
We developed a cohort state-transition model to reflect the treatment pathway in CIC from the UK NHS and personal social services perspective. Time on treatment was determined by a treatment continuation rule using data from an indirect comparison and survival curves fitted to long-term data. Quality of life was defined by whether CIC was resolved or unresolved, using published values. Costs were determined by drug acquisition costs, invasive procedures and healthcare resource use (associated with resolved or unresolved CIC), using published UK sources. Deterministic and probabilistic sensitivity analyses were conducted.

RESULTS
Over a 10-year time horizon, lubiprostone was more costly and more effective than placebo and immediate referral to secondary care, with incremental cost-effectiveness ratios (ICERs) of £58,979 and £21,152. Lubiprostone dominated prucalopride in the base case and with a time horizon of 1 year. The main sensitivity for the comparison against placebo was the assumptions around placebo cost and efficacy. The main sensitivity for the comparison against prucalopride was the endpoint used in the indirect comparison.

CONCLUSION
Lubiprostone may be cost effective compared with prucalopride or immediate referral but not compared with placebo in the base case. The implementation of the guidance issued by NICE should increase quality of life for patients with CIC and provide a further treatment option.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen + twenty =

[ HIDE/SHOW ]